• Lonza launches next-generation 4D-Nucleofector® Platform, the leading non-viral cell transfection method for a wide variety of cell types – even those traditionally hard to transfect
• Modular design offers unmatched flexibility in scale and throughput with proven performance
• 4D-Nucleofector® Core Unit with user experience upgrade for even more intuitive experimental setup and data management
  
  Quote from Dr. Nina Novak, Product Manager Nucleofection® Technology, Lonza:
  “The Nucleofector® Technology has been used for more than 10,000 peer-reviewed publications since its introduction 20 years ago, clearly demonstrating its importance for this community of successful researchers. The system is widely recognized as the most efficient non-viral cell transfection method – especially for hard-to-transfect cells, such as immune cells. The next-generation 4D-Nucleofector® Platform brings UX improvements that make the system even more intuitive and easy to use, firmly securing its place as a core method in cell-based research.”

Lonza has launched the next generation of its popular Nucleofector® Platform. For more than 20 years, Nucleofector® Technology has led the market as the most effective non-viral cell transfection method, which can be used even for hard-to-transfect cells, such as primary cells and pluripotent stem cells. Now, with an updated core unit and even more intuitive software, the next generation 4D-Nucleofector® Platform delivers flexibility and the same trusted performance with even greater ease of use.

Electroporation, the method by which DNA, RNA or protein is introduced into cells through an electrical pulse to change their genotype or phenotype, is an important tool with a range of applications in disease research and drug discovery, as well as in the advancement of gene therapies, immunotherapies and stem cell generation. The Nucleofector® Technology achieves high transfection efficiency in union with high cell viability by providing unique electrical pulses, cell type-specific solutions, and optimized protocols to achieve an advanced electroporation approach that targets the cell’s nucleus directly. This powerful combination leads to reproducible, faster, and more efficient results than other methods.

The 4D-Nucleofector® Core Unit can operate up to three functional modules, allowing for tailored experimental setups and facilitating scale-up from low to high-volume transfection. In the next generation, the family of units is now joined by a fully integrated 96-well unit to suit users with mid-scale transfection requirements for up to 96 samples at once. In addition, the updated Core Unit features an 8-inch touchscreen display, enabling users to easily set up their experiments and control all functional modules via the system’s intuitive and user-friendly software. Further, optimized protocols are available for more than 750 different cell types and are designed to provide robust transfection conditions, leading to optimal results every time.

The second generation Nucleofector® Units include:

• 4D-Nucleofector® X Unit – for various cell numbers in 100 µL cuvettes or 20 µL 16-well strips
• 4D-Nucleofector® Y Unit – for transfection of cells in adherence in 24-well culture plates
• 4D-Nucleofector® LV Unit – for closed, scalable large-volume transfection of up to 1x10⁹ cells
• 4D-Nucleofector 96-well Unit – for simultaneous transfection of up to 96 samples at once
  
  With the Nucleofector® System, small-scale protocols can be transferred to a larger scale without the need for re-optimization, bringing together small- and large-scale transfection applications in a single system.

For 20 years, scientists have relied on the Nucleofector® Technology to power their research. With the introduction of the next generation 4D-Nucleofector® Platform, users will be able to achieve high transfection efficiencies more easily with the reassurance that their protocols can be effortlessly scaled as needed.

For more information on the Nucleofector® Technology, visit Lonza.com/new-4D-Nucleofector.

About Lonza
Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector.

Founded in 1897 in the Swiss Alps, today Lonza operates across five continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion. Find out more at www.lonza.com

Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter

Additional Information and Disclaimers
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

The Nucleofector® Technology is covered by patent and/or patent pending rights owned by the Lonza Group Ltd or its affiliates. Any user must make his own determination and satisfy himself that the products supplied by Lonza Group Ltd or its affiliates and the information and recommendations given by Lonza Group Ltd or its affiliates are (i) suitable for intended process or purpose, (ii) in compliance with environmental, health and safety regulations, and (iii) will not infringe any third party’s intellectual property rights. The user bears the sole responsibility for determining the existence of any such third party rights, as well as obtaining any necessary licenses.